Clinical Trial Update: Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating stem cell mobilization with Plerixafor for an immunologic reset in Type 1 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Mozobil (plerixafor)

Snippet

Sponsor: University of Alberta | Conditions: Diabetes Mellitus, Type 1 | Phase 1, Phase 2 | Status: COMPLETED